Investor Day

Investor Day February 7, 2022

Disclaimer FORWARD-LOOKING STATEMENTS AND NON-GAAP MEASURES Safe Harbor

Statement under the Private Litigation Reform Act of 1995 This presentation contains forward-looking statements within the meaning of federal securities laws, including, among others, any statements about our expectations, plans, intentions,

strategies or prospects. We generally use the words may, will, expects, believes, anticipates, plans, estimates, projects, assumes,

guides, targets, forecasts, sees, seeks, should, could, would, predicts, potential, strategy, future,

opportunity, work toward, intends, guidance, confidence, positioned, design, strive, continue, look forward to and similar

expressions to identify forward-looking statements. All statements other than statements of historical or current fact are, or may be deemed to be, forward-looking statements. Such statements are based upon the current beliefs, expectations and

assumptions of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially from the forward-looking statements. These risks, uncertainties and changes

in circumstances include, but are not limited to: the effects of the COVID-19 global pandemic and other adverse public health developments on the global economy, our business and operations and the business

and operations of our suppliers and customers, including the deferral of elective procedures and our ability to collect accounts receivable; dependence on new product development, technological advances and innovation; shifts in the product category

or regional sales mix of our products and services; supply and prices of raw materials and products; pricing pressures from competitors, customers, dental practices and insurance providers; changes in customer demand for our products and services

caused by demographic changes or other factors; challenges relating to changes in and compliance with governmental laws and regulations affecting our US and international businesses, including regulations of the FDA and foreign government

regulators, such as more stringent requirements for regulatory clearance of products; competition; the impact of healthcare reform measures; reductions in reimbursement levels by third-party payors; cost containment efforts sponsored by government

agencies, legislative bodies, the private sector and healthcare group purchasing organizations, including the volume-based procurement process in China; control of costs and expenses; dependence on a limited number of suppliers for key raw materials

and outsourced activities; the ability to obtain and maintain adequate intellectual property protection; breaches or failures of our information technology systems or products, including by cyberattack, unauthorized access or theft; the ability to

retain the independent agents and distributors who market our products; our ability to attract, retain and develop the highly skilled employees we need to support our business; the effect of mergers and acquisitions on our relationships with

customers, suppliers and lenders and on our operating results and businesses generally; a determination by the IRS that the distribution or certain related transactions should be treated as taxable transactions; expected financing transactions

undertaken in connection with the separation and risks associated with additional indebtedness; the impact of the separation on our businesses and the risk that the businesses will not be separated successfully or such separation may be more

difficult, time-consuming and/or costly than expected, which could impact our relationships with customers, suppliers, employees and other business counterparties; restrictions on activities following the distribution in order to preserve the tax-free treatment of the distribution; the ability to form and implement alliances; changes in tax obligations arising from tax reform measures, including EU rules on state aid, or examinations by tax authorities;

product liability, intellectual property and commercial litigation losses; changes in general industry and market conditions, including domestic and international growth rates; changes in general domestic and international economic conditions,

including interest rate and currency exchange rate fluctuations; and the impact of the ongoing financial and political uncertainty on countries in the Euro zone on the ability to collect accounts receivable in affected countries. You are cautioned

not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. Forward-looking statements speak only as of the date they are made, and we expressly disclaim any

intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Non-GAAP Financial Measures This presentation contains financial

measures which have not been calculated in accordance with United States generally accepted accounting principles ( GAAP ), because they are a basis upon which our management assesses our performance. Although we believe these measures may

be useful for investors for the same reason, these financial measures should not be considered as an alternative to GAAP financial measures as a measure of our financial condition, profitability and performance or liquidity. In addition, these

financial measures may not be comparable to similar measures used by other companies. In the Appendix to this presentation, we provide further descriptions of these non-GAAP measures and reconciliations of

these non-GAAP measures to the corresponding most closely related GAAP measures.

Agenda Time (EST) Topics Presenter 11:00 11:05am Welcome Vafa Jamali Introduction to ZimVie CEO 11:05

11:30am Business Highlights Indraneel Kanaglekar 11:30am 12:00pm Overview of Dental Opportunity SVP, President of Global Dental Rebecca Whitney 12:00 12:40pm Overview of Spine Opportunity SVP, President of Global Spine Rich

Heppenstall 12:40 12:50pm Financial Overview CFO Vafa Jamali 12:55 1:00pm Wrap Up CEO 1:00 1:15pm Break All 1:15 1:45pm Q&A All

Indraneel Kanaglekar Rebecca Whitney Rich Heppenstall SVP, President, SVP, President, ZimVie Global Dental,

Global Spine, Chief Financial Officer ZimVie ZimVie [Graphic Appears Here] [Graphic Appears Here] [Graphic Appears Here] [Graphic Appears Here] Vafa Jamali ZimVie Chief Executive Officer

Why are we spinning off? To breathe new life, dedicated energy and strategic focus to our trusted brands and

Positioned to Capitalize on Multiple Opportunities for Growth 1 Well-positioned in large

and growing ~$20B global dental and spine markets 2 Comprehensive portfolio of trusted brands and products 3 Differentiated product profiles, supported by extensive clinical evidence 4 Established commercial infrastructure with global reach 5 Track

record of successful innovation Experienced management team with a focus on driving 6 long-term sustainable growth

Introduction to ZimVie Vafa Jamali Chief Executive Officer

ZimVie At A Glance ~$20B Global Market Opportunity ~$1B[1] Dental, 46% Third Party 2021E Sales Sales by #

Market Player # Market Player (unaudited) Segment 5 6 (2021E) Spine, in Dental in Spine 54% ~66%[2] 20+ Brands Trusted by Clinicians and Surgeons Worldwide Management Adjusted APAC, 12% 2021E Gross Margin 70+ Countries Served by EMEA, 13% ~2,700

Team Members [2,3] Sales by $132M Geography ~13% (2021E) Margin Years of Clinical Evidence Management Adj. EBITDA 20 Supporting Our Brands Americas, 2021E 75% [1] Excludes impact of related party transactions; includes $9 million in revenue

from exited markets [2] Management Adjusted EDITDA gives effect to the separation as if the Company had operated as an independent, publicly traded company for the full year 2021. These adjustments include, but are not limited to certain costs to

establish ourselves as a standalone public company and exclusion of other costs that we consider highly variable and are for a specified period of time. Refer to Appendix for further information [3] Management Adjusted EBITDA excludes share-based

compensation; goodwill impairment; integration, restructuring and other expenses; and other various costs. Refer to Appendix for further information

Well Known Brands with Established History Spine Dental EBI Pre-2016

2016 2019 2020 2021 2022 Acquisition of LDR to Acquisition of ZimVie becomes take the lead in 3DIEMME to expand independent publicly cervical disc digital dentistry traded company replacement portfolio 1988 1999 2003 2008 2008 Acquisition of Implant

Announces planned spin-ConciergeTM to enter off of Dental and Spine guided dental surgery businesses to form services market NewCo 2011

Vision Everyone deserves to feel better, healthier, and stronger. We create solutions for people to enjoy and

experience life. Mission Advancing clinical technology foundational to restoring daily life. Page 10 Our Core Values uriosity Authenticity Accountability Growth Mindset

Executing the Growth Plan Drive sustainable growth through innovation and market development in focused

categories Leverage experienced management team to identify and focus on the best opportunities for growth Strengthen the foundation: strategically, operationally, and commercially

ZimVie Transformation Focused on Value Creation Build Leadership & Talent Systems &

Operations Performance & Innovation ZimVie Pillar Team engagement scores Exited unprofitable geographies to Disciplined portfolio management increased to 80 from 60 s focus on

greatest opportunities Operating model improvements; Recent Historically revolving leadership Investments in digitization and lessons from COVID refreshed with a strong and automation of

manufacturing Progress experienced executive team Insourced spine manufacturing and Established patient-centric mission brand rationalization Drive accountability throughout the

Systematic continuous improvement Performance in fastest growing sub-organization Integrated & automated systems markets 2022+ Be a destination workplace

platform Innovation focus on growth drivers Adopt a growth mindset Financial flexibility for M&A

Business Highlights Vafa Jamali Chief Executive Officer

Patient Conditions We Serve In Our DENTAL An estimated 8 million US patients seek

treatment for tooth loss annually Only 25% receive tooth replacement Focus on increasing access to treatments with better outcomes for patients We improve smiles, function, and confidence in daily life Page 14 SPINE Spine-related disability is the

#1 reason people seek medical treatment Clinical outcomes have room to improve Focus on innovations that provide better outcomes for patients We reduce pain, increase mobility, and restore function to daily life

ZimVie is a Leading Player in a Large and Growing ~$20B Market Opportunity ZimVie Segments Category Market Size

($B) Segment Growth[1] Dental Implant Solutions $5.0 MSD Dental Biomaterials $1.0 MSD Digital Dentistry $2.0 HSD Core and Complex Solutions $8.5 LSD Bone Healing / EBI $0.5 LSD Spine Minimally Invasive Surgery (MIS); MSD $2.2 Enabling Technologies

Mid / High Teens Motion Preservation Devices $0.4 HSD [Segment Growth Definitions: LSD = Low Single Digit or 1-3%, MSD = Mid Single Digit or 4-6%, HSD = High Single

Dental Capabilities Fully Integrated

End-to-End Tooth Replacement Solutions Dental Implants ~300 In-House Full range of R&D Employees Tapered T3 Implant

abutments, Screw-Vent Across Spine & Dental copings and (TSV) analogs Collaboration with Surgeons, Clinicians, Biomaterials KOLs Xenograft and Barrier Puros Allograft synthetic bone Membranes grafts Strategic Partnerships Digital

Dentistry Encode System Tuck-in RealGUIDE GenTek Software SmileZ Today Acquisitions System BellaTek System

Spine Capabilities Comprehensive Product Portfolio Core and Complex Solutions ~300 In-House R&D Employees llOss Virage Vital Across Spine & Dental ROI-C PrimaGen Advanced MaxAn Allograft Collaboration with

Surgeons, Clinicians, Minimally Invasive Surgery Bone Healing / EBI KOLs Timberline Bone Healing Vital MIS Lateral Fusion Technologies Strategic Partnerships Motion Preservation Devices Tuck-in

Mobi-C The Tether Acquisitions Cervical Disc

Platforms Supported by Extensive Clinical Evidence 1,750+ peer-reviewed publications PUROS MOBI-C THE TETHER ALLOGRAFT First PMA-approved cervical The only FDA-approved device Family of allografts, clinically disc in the US.

Proven for anterior vertebral body documented to provide statistically superior to tethering to correct progressive predictable bone regeneration that fusion at 10 years[1] for two- idiopathic scoliosis; with

over 7 improves long-term success of level disc replacement years[2] of data implant procedures [1] Kim KD, Hoffman GA, Bae H, et al. Ten-Year Outcomes of One and Two Level Cervical Disc Arthroplasty from the

Mobi-C IDE Clinical Trial. Neurosurgery. 2021 Feb 16;88(3):E231. doi: 10.1093/neuros/nyaa459 [2] Data on file as part of G150001 FDA 2021 Annual Report

Global infrastructure

Focus on Delivering Long-Term Sustainable Growth Common Market Trends ging Global

Population Increasing Healthcare sumerism ovider Economics Pressures doption of echnology for utcomes ZimVie Growth Objectives Drive Commercial & Operational Focus Improving efficiency,

profitability, and cash flow Promote Clinically Superior Products Differentiated through extensive clinical evidence Deliver Advanced Workflow Solutions Driving pull-through and growth Key Growth Drivers Dental Spine Implant Mobi-C Growth Cervical

Disc Replacement Biomaterials Pull-Through The Tether for Pediatric Digital Dentistry Scoliosis Pull-Through MIS Procedural Geographic Solutions Expansion

Proven Executive Leadership Team Vafa Jamali Rich Heppenstall Heather Kidwell Indraneel Kanaglekar Rebecca

Whitney Chief Executive Officer EVP, Chief Financial Officer SVP, Chief Legal and SVP, President, SVP, President, Compliance Officer Global Dental Global Spine Michael Minette Ann Vu David Harmon SVP, Strategy & SVP, Regulatory Affairs SVP,

Chief Human Corporate Development and Quality Assurance Resources Officer Laura Driscoll Ben Hutson Stephen Rondeau VP, Communications SVP, Operations SVP, Chief Information Officer

Experienced Board of Directors Dave King Sally Crawford Vinit Asar Former Chairman and CEO, Former COO,

President, CEO and Director, LabCorp Healthsource, Inc. Hanger, Inc. Karen Matusinec Vafa Jamali Former SVP, Treasurer CEO and Director, McDonald s Corporation ZimVie

Positioned to Capitalize on Multiple Well-positioned in large and growing ~$20B global dental 1 Opportunities

and spine markets for Growth 2 Comprehensive portfolio of trusted brands and products 3 Differentiated product profiles, supported by extensive clinical evidence MSD% Growth 4 Established commercial infrastructure with global reach Flat Growth 5

Track record of successful innovation Experienced management team with a focus on driving Near-term 3 5 Years 6 long-term sustainable growth

Overview of Dental Opportunity Indraneel Kanaglekar SVP, President of Global Dental

Leading Dental Player with Strong Momentum ~$8B 3 $469M Global Tooth Submarkets Implants, Dental 2021E

Sales Replacement Market Biomaterials, Digital Dentistry (unaudited) #2 Best-in-Class 57% US Portfolio of Brands Trusted by 43% OUS Global Biomaterials [1, 2] Clinicians

and Surgeons Approximate Revenue Company (by revenue) Split in 2021E Presence in 93% 70+ MSD 3 5 Year % Countries including US, EU, of Sales Direct to Customers Growth Rate Japan, and China [1] Dental Biomaterials | Medtech 360 | Market

Insights | Europe | 2019 | www.DecisionResourcesGroup.com | pg. 10 [2] Dental Biomaterials | Medtech 360 | Market Insights | North America | 2019 | www.DecisionResourcesGroup.com | pg. 11

Tooth Replacement: ~$8B Market Growing at Mid Single Digits Major Trends Shaping Our Industry Market

Opportunity Macro: Dental Implant Solutions HSD Biomaterials growth 120M people in the US Digital Dentistry are missing at least one tooth (44% of individuals aged 15+) [1, 2, 3] MSD Aging Increasing Provider Adoption of ~$8B growth global

healthcare economic technology for Market population consumerism pressures outcomes 1 in 4 US patients 2 who seek treatment receive an implant [1, 2, 3] Industry-Specific: 1 MSD growth 5 Under penetration Consolidation of Adoption of Growth in

trained of dental implant dental practices digital workflow surgeons and dental therapy and labs solutions clinicians ~2M people in the US are treated annually 2021E 2026E [1] American College of Prosthodontists

https://www.gotoapro.org/facts-figures/ [2] Straumann 2019 annual report | pg. 29 [3] Internal analysis using DIMDC implant and WHO population data

Product Overview Key Products Key Competitors Dental Implants Implants, surgical tools, abutments, and other

restorative components for implant-based tooth Tapered Screw- Full range of abutments, T3 Implant replacement Vent (TSV) copings, and analogs Biomaterials Bone graft substitutes, membranes, and tissue Puros Xenograft and Barrier regenerative

products Allograft synthetic bone grafts Membranes Digital Solutions Patient-specific solutions, intraoral scanners, CAD/CAM equipment, treatment planning, and designing software and Encode RealGUIDE GenTek SmileZ surgical guides Software Today